SCHEMBL5951797

SCHEMBL5951797

Cc1ccc2[nH]c(-c3n[nH]c4ccccc34)nc2c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 7/20 0.58
▸ FLT1 P17948 5/20 0.58
▸ CHEK1 O14757 3/20 0.53
▸ CBFB Q13951 1/20 0.53
▸ ITK Q08881 6/20 0.53
▸ PDPK1 O15530 3/20 0.53
▸ CDK2 P24941 3/20 0.53
▸ KDR P35968 2/20 0.53
▸ PLK4 O00444 1/20 0.53
▸ AURKA O14965 1/20 0.53
▸ CHUK O15111 1/20 0.53
▸ JAK2 O60674 1/20 0.53
▸ ROCK2 O75116 1/20 0.53
▸ MAP4K4 O95819 1/20 0.53
▸ PAK4 O96013 1/20 0.53
▸ CHEK2 O96017 1/20 0.53
▸ ABL1 P00519 1/20 0.53
▸ NTRK1 P04629 1/20 0.53
▸ PRKCG P05129 1/20 0.53
▸ INSR P06213 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6280336 0.86 FGFR1 (0.56) FGFR1FLT1CHEK1ITKPDPK1
SCHEMBL3539166 0.86 FGFR1 (0.56) FGFR1FLT1CHEK1ITKPDPK1
SCHEMBL4912661 0.77 FGFR1 (0.70) FGFR1FLT1CHEK1CBFBITK
SCHEMBL13558782 0.76 FGFR1 (0.58) FGFR1CBFBITKPDPK1GAA
SCHEMBL3537073 0.75 FGFR1 (0.71) FGFR1FLT1CHEK1ITKPDPK1
SCHEMBL6885365 0.75 NPC1 (0.61) CBFBPKN2KDM4EALDH1A1GAA
SCHEMBL6373229 0.74 CBFB (0.63) CBFBRPS6KA3GAA
SCHEMBL29714859 0.74 FGFR1 (1.00) FGFR1FLT1CHEK1ITKPDPK1
SCHEMBL311148 0.74 FGFR1 (1.00) FGFR1FLT1CHEK1ITKPDPK1
SCHEMBL18562045 0.74 CDK2 (0.53) FGFR1FLT1CHEK1ITKCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US claimed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US claimed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US claimed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 — — US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 — — US disclosed
US-8288425-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2012-10-16 — — US disclosed
US-20060014756-A1 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2006-01-19 — — US disclosed
US-6897208-B2 Benzimidazoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 — — US disclosed
EP-1441725-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS Aventis Pharmaceuticals Inc. (US) 2004-08-04 — — EP disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014756-A1 Benzimidazoles CDK9, BMX, SBK3 FGFR1 583/4885FLT1 2074/4885CHEK1 286/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A FGFR1 254/4885FLT1 1117/4885CHEK1 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback